Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.JzBkOQ-g.js ...

Now that the year is underway and a new presidential administration is in place in Washington, let’s consider the environment ...

Pfizer reported $63.6 billion in revenue for the full year, up 7% compared to 2023. The full-year revenue beat Wall Street ...

Despite continued underperformance in 2024, the biotech sector enters 2025 with a brighter outlook driven by groundbreaking ...

While the world waits an effective coronavirus vaccine, Eli Lilly has started late-stage human testing an antibody drug as an alternative way to prevent viral transmission in high-risk locations.

Healthcare sector shows strong performance in January amid signs of a brighter 2025, according to analysts. Read more here.

With vaccines and drugs for COVID-19 now in late-stage development, companies are moving swiftly to lay down the capacity to make them at scale, as new deals for BioNTech and Eli Lilly this week ...

In recent years, the pharmaceutical industry has undergone significant changes in the focus of its innovation, research and ...

Subin Baral, EY global life sciences deals leader, told GEN M&A deals are expected to increase in 2025, driven by biopharmas that are eager to recoup revenues they expect to lose as their aging ...

A group of lawmakers are urging President Donald Trump to reject pharmaceutical companies’ efforts to pause the Biden administration’s drug-price cuts.

On the clinical side, we saw GSK shell out just over $1 billion for gastrointestinal cancer specialists IDRx, while Eli ... vaccines against common viral infections, such as COVID-19 or the ...